As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detected, stratified, and monitored. Yet these companies often face unique challenges in capital formation. This session brings together investors, entrepreneurs, strategic corporate partners, and non-dilutive funding leaders to examine how financing strategies for diagnostics and precision medicine are evolving in response to these challenges. Panelists will explore how venture, strategic, and public capital assess diagnostic companies across stages, highlighting differences in capital efficiency, timelines, and risk profiles compared to drug development. Attendees will gain practical insights into how diagnostics companies are being financed today, what investors look for at different stages of growth, and how founders can navigate capital formation in a rapidly evolving innovation landscape.